Livedoid vasculopathy: how to diagnose and how to treat?

D Lipsker¹

Affiliations

Comment

D Lipsker. J Eur Acad Dermatol Venereol. 2019 Sep.

. 2019 Sep;33(9):1627-1628.

doi: 10.1111/jdv.15830.

D Lipsker¹

¹ Faculté de Médecine, Clinique Dermatologique, Université de Strasbourg et Hôpitaux Universitaires, Strasbourg, France.

No abstract available

Comment on

Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, Eveslage M, Drabik A, Goerge T. Weishaupt C, et al. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1784-1791. doi: 10.1111/jdv.15639. Epub 2019 May 14. J Eur Acad Dermatol Venereol. 2019. PMID: 31009111 Clinical Trial.

1. Weishaupt C, Strölin A, Kahle B et al. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis. J Eur Acad Dermatol Venereol 2019; 33: 1784-1791.
1. Weishaupt C, Strölin A, Kahle B et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 2016; 3: e72-e79.
1. Gardette E, Moguelet P, Bouaziz JD et al. Livedoid vasculopathy: a French observational study including therapeutic options. Acta Derm Venereol 2018; 98: 842-847.
1. Yamaguchi Y, Nakazato S, Izumi K, Ieko M, Nomura T, Shimizu H. Rapid remission of severe pain from livedoid vasculopathy by apixaban. J Eur Acad Dermatol Venereol 2017; 31: e45-e46.
1. Drerup C, Goerge T. Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban. J Eur Acad Dermatol Venereol 2017; 31: e532.